BeyondSpring (BYSI) Now Covered by Seaport Global Securities

Equities researchers at Seaport Global Securities began coverage on shares of BeyondSpring (NASDAQ:BYSI) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating and a $56.00 price target on the stock. Seaport Global Securities’ price objective would suggest a potential upside of 77.27% from the stock’s current price.

Several other research firms have also issued reports on BYSI. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of BeyondSpring in a research note on Monday, August 21st. Maxim Group assumed coverage on BeyondSpring in a research note on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Zacks Investment Research lowered BeyondSpring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $54.50.

BeyondSpring (BYSI) opened at $31.59 on Tuesday. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49.

BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. equities analysts expect that BeyondSpring will post -4.41 EPS for the current year.

An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned approximately 0.10% of BeyondSpring at the end of the most recent quarter. 1.22% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply